XBiotech Inc.
NASDAQ:XBITBiotechnology
-$0.02 today
- Market cap
- $52.74M
- Beta
- 0.84
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.32
Volume 0.06M
Average 0.03M
XBIT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
XBiotech Inc.NASDAQ: XBIT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $5.51M (cash outflow) fell 49.4% year over year, behind the +1.9% change in trailing-twelve-month net income. Sequentially, it fell 79.5% from the prior quarter. Over 3 fiscal years it compounded at +11.4% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether next quarter's net income reaches the consensus estimate of $914.63K, a +152.1% change from the same quarter last year.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.51M-79.5% QoQ
- Last fiscal yearDec 2025
- -$45.54M+18.2% YoY
- LTMMar 2026
- -$40.16M+1.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -49.4% | +152.1% | +201.5 pp |
| 1 year | +18.2% | — | — |
| 3-year CAGR | +11.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (45.54M) USD
- Year-over-year change
- -18.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.54M) | -18.2% |
| FY2024 | 2024-12-31 | (38.53M) | -56.9% |
| FY2023 | 2023-12-31 | (24.56M) | +25.4% |
| FY2022 | 2022-12-31 | (32.9M) | -88.9% |
| FY2021 | 2021-12-31 | (17.41M) | — |
Net Income vs competitors
How XBIT compares with its peers on the latest reported figures
- XBIT's LTM Mar 2026 net income of $40.16M is the 6th largest of the 9 companies compared; the peer median is $45.36M.
- Its year-over-year change of +1.9% is the 2nd highest of 8, against a peer median of -7.2%.
- Over three fiscal years its annual growth of +11.4% compares with a peer median of +11.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $108.83M | -7.2% | +18.7% | — | |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $40.16M | +1.9% | +11.4% | — | |
| LTM Jun 2024 | $31.85M | — | -39.6% | 3904.3% | |
| LTM Mar 2026 | $21.24M | +1.5% | +4.7% | — | |
| LTM Apr 2026 | $8.08M | -19.0% | +22.4% | 448.4% | |
| Peer median (excluding XBIT) | $45.36M | -7.2% | +11.7% | 904.5% | |
Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.41M) | (32.9M) | (24.56M) | (38.53M) | (45.54M) |
| Depreciation & Amortization | 2.65M | 2.61M | 1.74M | 1.75M | 1.69M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 5K |
| Stock-Based Compensation | 4.46M | 5.06M | 3.26M | 1.75M | 3.62M |
| Change in Working Capital | 79.75M | 7.6M | 2.72M | (1.46M) | 3.64M |
| Accounts Receivables | 1.73M | 7.34M | 829K | 77K | 574K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (514K) | 357K | 91K | (364K) | (688K) |
| Other Working Capital | 78.53M | (97K) | 1.8M | (1.17M) | 3.75M |
| Other Non-Cash Items | 4.46M | 2.8M | (1.89M) | 5.53M | (3.33M) |
| Operating Cash Flow | 69.45M | (14.82M) | (18.73M) | (30.96M) | (39.92M) |
| Capital Expenditures | (3.53M) | (585K) | (362K) | (1.3M) | (289K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (63.31M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 61.86M | 0 | 0 |
| Investing Cash Flow | (3.53M) | (63.89M) | 61.5M | (1.3M) | (289K) |
| Debt Repayment | 0 | 0 | 0 | 10.25M | (10.25M) |
| Common Stock Issued | 0 | 0 | 5K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (75M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8M | 0 | (14K) | 200K | 0 |
| Financing Cash Flow | (67.01M) | 0 | (9K) | 10.45M | (10.25M) |
| Effect of Forex Changes | 705K | (961K) | (46K) | (5.53M) | 3.33M |
| Net Change in Cash | (383K) | (79.68M) | 42.72M | (27.35M) | (47.13M) |
| Free Cash Flow | 65.92M | (15.41M) | (19.09M) | (32.27M) | (40.21M) |
XBiotech Inc.
NASDAQ:XBIT
Intrinsic Alpha fair value
Locked
Current Price
$1.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.